Lumicks–de Wit H: management, 202405– CEO before Sartorius + Cellca + Pangenetics + Siegfried + Merck + Lonza

	Period	2024-05-29
	Organisation	Lumicks Technologies B.V.
	Group	Lumicks (Group)
	Product	cell analysis technology
	Product 2	cell culture technology
	Person	Heyning, Olivier (Lumicks –202104–202405 CEO LEFT 5/24)

Lumicks Technologies B.V.. (5/29/24). "Press Release: Lumicks Appoints Hugo de Wit as CEO and Executive Board Director". Amsterdam.

Life Sciences Veteran Joins To Accelerate Company Growth

LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced that Hugo de Wit has been appointed Chief Executive Officer, based in the Company’s headquarters in Amsterdam.

Olivier Heyning, the previous CEO of LUMICKS, said, “After leading the company for 10 years, the board and I believe now is the right time to begin this transition. We are confident in Hugo’s leadership to build upon the strong foundation we’ve established. It has been a privilege to co-found and lead LUMICKS. I look forward to continuing my engagement with the company and working with Hugo to ensure a smooth transition.”

Ms. McLaughlin, Chair of the Board, added, “We are thrilled to welcome Hugo de Wit to LUMICKS as the new CEO. Hugo brings extensive global leadership and commercial experience, a proven track record, and relevant knowledge of the industry. His experience will be invaluable as the company continues to grow and unlock new market opportunities. We thank Olivier Heyning for his tremendous contributions to co-founding and growing LUMICKS into the successful company it is today, and we look forward to working together in the future.”

Mr. de Wit brings more than 30 years of experience in leading high-value strategic life science, leading multi-cultural and cross-functional teams, in scaling SMEs and larger corporations. Mr. de Wit comes from Sartorius where he held several roles. Most recently he served as Head of Business Area Cell Culture Technologies where he led the development and marketing of the bioreactor, software, and cell culture media portfolio. Before that, Mr. de Wit worked for Lonza, Merck, Siegfried, and Pangenetics before joining Cellca GmbH in 2010 as CEO which was acquired by Sartorius in 2015.

Mr. de Wit holds a Master of Science degree in bioprocess technology from the University of Wageningen, an executive MBA degree from the GSBA and Robert H. Smith Business School from the State University of Maryland.

“I am excited to join LUMICKS for its people, technology, and products with their fascinating applications and the opportunity to realize with the teams the full potential and impact of the company’s inventions for customers and the life science industry”, said Hugo de Wit.

About LUMICKS

LUMICKS is a leading life science tools company specialized in Dynamic Single-Molecule and Cell Avidity analysis, two rapidly advancing fields in biology research and immuno-oncology drug discovery. LUMICKS’ instruments allow researchers, for the first time, to bridge the crucial and yet unfinished gap between structure and function at both the molecular and cellular level.

By combining advanced imaging techniques with application and measurement of forces, LUMICKS enables revealing crucial real-time insights on biological mechanisms: “See More. Know More”. LUMICKS’ C-Trap® Optical Tweezers – Fluorescence technology, allows scientists to analyze complex biological processes in real-time. The z-Movi® Cell Avidity Analyzer enables the measurement and selection of immune cells based on their interaction with tumor cells.

For more information contact:

Chenlu Yu, media contact
PR@lumicks.com